Free Trial

Novan (NOVN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
7.19 million shs
Average Volume
602,421 shs
Market Capitalization
$2.64 million
P/E Ratio
Dividend Yield
Price Target
NOVN stock logo

About Novan Stock (NASDAQ:NOVN)

Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.

NOVN Stock News Headlines

Novartis AG
Novartis AG Registered Shares
Novartis AG Registered Shares NOVN
Novan reaches deals to sell assets in bankruptcy case
Firm Retention Summary: Novan
Novan cuts 50% of its workforce to extend runway
Novan To "Sharpen" Focus, Resources On Berdazimer Gel
NOVN: Counting Down to PDUFA
Novan earnings: here's what Wall Street expects
Earnings Preview: Novan
Novan Q1 2023 Earnings Preview
See More Headlines
Receive NOVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$24.71 million
Book Value
$0.19 per share


Free Float
Market Cap
$2.64 million
Not Optionable
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Ms. Paula Brown Stafford M.P.H. (Age 58)
    Pres, CEO & Chairwoman
    Comp: $623.23k
  • Mr. John M. Gay CPA (Age 46)
    CFO, Principal Accounting Officer & Corp. Sec.
    Comp: $386.89k
  • Mr. John A. Donofrio Jr. (Age 56)
    Exec. VP & COO
    Comp: $602.51k
  • Dr. Carri Geer Ph.D.
    Sr. VP & CTO
  • Dr. Tomoko Maeda-Chubachi M.B.A.
    M.D., Ph.D., Chief Medical Officer

NOVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Novan stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NOVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NOVN, but not buy additional shares or sell existing shares.
View NOVN analyst ratings
or view top-rated stocks.

How were Novan's earnings last quarter?

Novan, Inc. (NASDAQ:NOVN) issued its quarterly earnings data on Monday, May, 15th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.22. The business earned $3.17 million during the quarter, compared to analyst estimates of $6.19 million. Novan had a negative trailing twelve-month return on equity of 700.28% and a negative net margin of 128.61%. During the same period in the previous year, the business posted ($0.71) earnings per share.

What other stocks do shareholders of Novan own?
When did Novan IPO?

Novan (NOVN) raised $46 million in an IPO on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

This page (NASDAQ:NOVN) was last updated on 5/29/2024 by Staff

From Our Partners